JP6664329B2 - コンジュゲーションのための新規な細胞毒性チューブリシン化合物 - Google Patents

コンジュゲーションのための新規な細胞毒性チューブリシン化合物 Download PDF

Info

Publication number
JP6664329B2
JP6664329B2 JP2016549329A JP2016549329A JP6664329B2 JP 6664329 B2 JP6664329 B2 JP 6664329B2 JP 2016549329 A JP2016549329 A JP 2016549329A JP 2016549329 A JP2016549329 A JP 2016549329A JP 6664329 B2 JP6664329 B2 JP 6664329B2
Authority
JP
Japan
Prior art keywords
group
alkyl
formula
heteroalkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016549329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507926A (ja
Inventor
リヒター，ボルフガング
Original Assignee
トゥーベ・ファルマシューティカルズ・ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トゥーベ・ファルマシューティカルズ・ゲー・エム・ベー・ハー filed Critical トゥーベ・ファルマシューティカルズ・ゲー・エム・ベー・ハー
Publication of JP2017507926A publication Critical patent/JP2017507926A/ja
Application granted granted Critical
Publication of JP6664329B2 publication Critical patent/JP6664329B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016549329A 2014-01-28 2015-01-28 コンジュゲーションのための新規な細胞毒性チューブリシン化合物 Active JP6664329B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000291.6 2014-01-28
EP14000291 2014-01-28
PCT/EP2015/000161 WO2015113760A1 (en) 2014-01-28 2015-01-28 Cytotoxic tubulysin compounds for conjugation

Publications (2)

Publication Number Publication Date
JP2017507926A JP2017507926A (ja) 2017-03-23
JP6664329B2 true JP6664329B2 (ja) 2020-03-13

Family

ID=50028724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549329A Active JP6664329B2 (ja) 2014-01-28 2015-01-28 コンジュゲーションのための新規な細胞毒性チューブリシン化合物

Country Status (8)

Country Link
US (2) US10183970B2 (es)
EP (1) EP3099681B1 (es)
JP (1) JP6664329B2 (es)
CN (1) CN106132959B (es)
AU (1) AU2015213106B2 (es)
CA (1) CA2940311C (es)
ES (1) ES2843537T3 (es)
WO (1) WO2015113760A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
GB201402009D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
GB201402006D0 (en) * 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
US10723727B2 (en) * 2016-02-01 2020-07-28 Pfizer Inc. Tubulysin analogs and methods for their preparation
EP3429575A4 (en) 2016-03-16 2019-10-23 Purdue Research Foundation AGAINST CARBOANHYDRASE-IX DRUGS AND METHODS
JP2019515880A (ja) 2016-03-16 2019-06-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 炭酸無水酵素ｉｘ阻害剤抱合体およびその使用
EP3438118B1 (en) 2016-03-29 2023-03-29 Toray Industries, Inc. Peptide derivative and use thereof
EA202191769A1 (ru) * 2018-12-21 2021-12-08 Регенерон Фармасьютикалз, Инк. Тубулизины и конъюгаты белок-тубулизин
AU2021296449A1 (en) * 2020-06-24 2023-01-19 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080064908A (ko) * 2000-06-28 2008-07-09 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
EP1521769B1 (de) * 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
DE10254439A1 (de) * 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
AU2005244980B2 (en) * 2004-05-19 2011-09-15 E. R. Squibb & Sons, L.L.C. Chemical linkers and conjugates thereof
WO2008106080A2 (en) * 2007-02-27 2008-09-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of desacetoxytubulysin h and analogs thereof
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011069116A1 (en) 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
SG187728A1 (en) * 2010-08-06 2013-03-28 Endocyte Inc Processes for preparing tubulysins
RU2617402C2 (ru) * 2011-06-10 2017-04-25 Мерсана Терапьютикс, Инк. Конъюгаты белок-полимер-лекарственное средство
BR112014013526A2 (pt) * 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
US20140080175A1 (en) * 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
US20140017265A1 (en) * 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
EP3348280A1 (en) 2012-07-12 2018-07-18 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
EP2708243A1 (en) * 2012-09-17 2014-03-19 OntoChem GmbH Receptor ligand linked cytotoxic molecules
CN108042811A (zh) * 2012-11-15 2018-05-18 恩多塞特公司 用于治疗由psma表达细胞引起的疾病的共轭物
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation

Also Published As

Publication number Publication date
AU2015213106B2 (en) 2019-07-25
US10183970B2 (en) 2019-01-22
US10889616B2 (en) 2021-01-12
ES2843537T3 (es) 2021-07-19
AU2015213106A1 (en) 2016-09-01
CA2940311A1 (en) 2015-08-06
EP3099681A1 (en) 2016-12-07
EP3099681B1 (en) 2020-12-09
US20160340386A1 (en) 2016-11-24
CN106132959B (zh) 2020-04-17
CA2940311C (en) 2022-12-13
WO2015113760A1 (en) 2015-08-06
CN106132959A (zh) 2016-11-16
JP2017507926A (ja) 2017-03-23
US20190233471A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
JP6664329B2 (ja) コンジュゲーションのための新規な細胞毒性チューブリシン化合物
ES2463693T3 (es) Derivados de tubulisina
AU2015273098B2 (en) Auristatin derivatives and conjugates thereof
JP6871858B2 (ja) 抗体薬物コンジュゲート
KR20170102981A (ko) 헤테로아릴렌-가교된 벤조디아제핀 이량체, 그의 접합체, 및 제조 및 사용 방법
CN105722851A (zh) 一种新型的连接子及其制备方法和用途
JP7296396B2 (ja) アマニチン類抗体複合物
FR2626882A1 (fr) Conjugues de derives de vinca comportant une chaine detergente en position c-3
EP2499152A1 (en) Tubulin inhibitors
KR20160142885A (ko) 친화성 약제 컨쥬게이트
JP2015531794A (ja) 受容体リガンドにリンクされる細胞傷害分子
JP7292751B2 (ja) 抗体薬物複合体用薬物リンカーｍｃ－ｍｍａｆの調製方法及びその中間体
EP3335734A1 (en) Linker-drug and antibody-drug conjugate (adc) employing the same
KR20190039570A (ko) 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법
JP7076433B2 (ja) 新規細胞傷害性剤およびそのコンジュゲート
Stone et al. An approach to a synthetic carboxylate-binding pocket based on β-avoparcin
JP7335260B2 (ja) 非天然アマニチン類抗体複合物
Rigaudy et al. Synthesis and binding properties to DNA and to opioid receptors of enkephalin‐ellipticinium conjugates
US9765077B2 (en) Synthesis of duocarmycin analogues
CN114409562B (zh) 一种ca4衍生物及其配体-药物偶联物
Jayashankaran et al. A facile entry into a novel class of dispiroheterocycles through 1, 3-dipolar cycloaddition
EP4035684A1 (en) Affinity illudofulvene conjugates
WO2024150132A1 (en) Ligand-drug conjugates
CN117298291A (zh) Fc结合肽偶联物、靶向TROP2的定点偶联ADC及其制备方法和应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200218

R150 Certificate of patent or registration of utility model

Ref document number: 6664329

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250